Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second of two planned phase II trials of betalutin for the treatment of non-Hodgkin's lymphoma

Trial Profile

Second of two planned phase II trials of betalutin for the treatment of non-Hodgkin's lymphoma

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium-177 lilotomab satetraxetan (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PARADIGME
  • Most Recent Events

    • 24 Aug 2016 According to a Nordic Nanovector media release, optimized dose regimen of Lymrit 37-01 study will be used in PARADIGME study which is planned to start in 2H 2017.
    • 15 Apr 2016 According to a Nordic Nanovector media release, the pivotal PARADIGME study expected to start in Q1 2017.
    • 17 Nov 2015 According to Nordic Nanovector media release, based on the data from this and other trial the company plan for regulatory submission for Betalutin as a 3rd line treatment for patients with follicular lymphoma (FL) in first half of 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top